PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer

Authors: Saw, Stephanie P.L., Ng, Win Pin, Zhou, Siqin, Lai, Gillianne G.Y., Tan, Aaron C., Ang, Mei-Kim, Lim, Wan-Teck, Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Tan, Wan Ling, Rajasekaran, Tanujaa, Chan, Johan W.K., Teh, Yi Lin, Pang, Mengyuan, Yeo, Jia-Chi, Takano, Angela, Ong, Boon-Hean, Tan, Eng-Huat, Tan, Sze Huey, Skanderup, Anders J., Tan, Daniel S.W.

Source: European journal of cancer. 178:139-149

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100177957903.0x000001&indx=1&recIds=ETOCvdc_100177957903.0x000001

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

Authors: Lai, Gillianne G.Y., Yeo, Jia Chi, Jain, Amit, Zhou, Siqin, Pang, Mengyuan, Alvarez, Jacob J.S., Sim, Ngak Leng, Tan, Aaron C., Suteja, Lisda, Lim, Tze Wei, Guo, Yu Amanda, Shen, Meixin, Saw, Stephanie P.L., Rohatgi, Neha, Yeong, Joe P.S., Takano, Angela, Lim, Kiat Hon, Gogna, Apoorva, Too, Chow Wei, Da Zhuang, Kun, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Ang, Mei Kim, Rajasekaran, Tanujaa, Wang, Lanying, Toh, Chee Keong, Lim, Wan-Teck, Tam, Wai Leong, Tan, Sze Huey, Skanderup, Anders M.J., Tan, Eng-Huat, Tan, Daniel S.W.

Source: In JTO Clinical and Research Reports December 2022 3(12)

Characteristics and Outcomes of Airway Involvement in Esophageal Cancer

Authors: Goh, Ken Junyang, Lee, Pyng, Foo, Andrea Zhi Xin, Tan, Eng Huat, Ong, Hock Soo, Hsu, Anne Ann Ling

Source: In The Annals of Thoracic Surgery September 2021 112(3):912-920

Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Authors: Yeong, Joe, Suteja, Lisda, Simoni, Yannick, Lau, Kah Weng, Tan, Aaron C., Li, Hui Hua, Lim, Sherlly, Loh, Jie Hua, Wee, Felicia Y.T., Nerurkar, Sanjna Nilesh, Takano, Angela, Tan, Eng Huat, Lim, Tony K.H., Newell, Evan W., Tan, Daniel S.W.

Source: In Journal of Thoracic Oncology August 2021 16(8):1349-1358

Immune checkpoint inhibitor‐associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series

Authors: Wong, Evelyn Yi Ting, Yong, Ming Hui, Yong, Kok Pin, Tan, Eng Huat, Toh, Chee Keong, Kanesvaran, Ravindran, Takano, Angela, Ng, Quan Sing

Source: Asia-Pacific journal of clinical oncology. 17(5):e262-e267

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100132301813.0x000001&indx=1&recIds=ETOCvdc_100132301813.0x000001

Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

Authors: Ang, Mei‐Kim, Montoya, Jose Enrique, Tharavichitkul, Ekkasit, Lim, Cindy, Tan, Terence, Wang, Lan Ying, Wee, Joseph, Soong, Yoke‐Lim, Fong, Kam‐Weng, Ng, Quan Sing, Tan, Daniel Shao‐Weng, Toh, Chee‐Keong, Tan, Eng‐Huat, Lim, Wan‐Teck

Source: Head & neck. 43(5):1641-1651

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100120099106.0x000001&indx=1&recIds=ETOCvdc_100120099106.0x000001

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

Authors: Tan, Aaron C., Lai, Gillianne G.Y., Tan, Gek San, Poon, Shou Yu, Doble, Brett, Lim, Tse Hui, Aung, Zaw Win, Takano, Angela, Tan, Wan Ling, Ang, Mei-Kim, Tan, Bien Soo, Devanand, Anantham, Too, Chow Wei, Gogna, Apoorva, Ong, Boon-Hean, Koh, Tina P.T., Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Rajasekaran, Tanujaa, Lim, Alvin S.T., Lim, Wan Teck, Toh, Chee Keong, Tan, Eng-Huat, Lim, Tony Kiat Hon, Tan, Daniel S.W. ^*

Source: In Lung Cancer January 2020 139:207-215

Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma

Authors: Mesia, Ricard, Bossi, Paolo, Hansen, Aaron R., Hsieh, Ching-Yun, Licitra, Lisa F., Tan, Eng-Huat, Chen, Peng, Miller, JulieAnn, Siu, Lilian L., Haddad, Robert I.

Source: In European Journal of Cancer December 2019 123:138-145

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Authors: Halmos, Balazs, Tan, Eng-Huat, Soo, Ross A., Cadranel, Jacques, Lee, Min Ki, Foucher, Pascal, Hsia, Te-Chun, Hochmair, Maximilian, Griesinger, Frank, Hida, Toyoaki, Kim, Edward, Melosky, Barbara, Märten, Angela, Carcereny, Enric

Source: In Lung Cancer January 2019 127:103-111

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Authors: Solomon, Benjamin J ^*, Besse, Benjamin, Bauer, Todd M, Felip, Enriqueta, Soo, Ross A, Camidge, D Ross, Chiari, Rita, Bearz, Alessandra, Lin, Chia-Chi, Gadgeel, Shirish M, Riely, Gregory J, Tan, Eng Huat, Seto, Takashi, James, Leonard P, Clancy, Jill S, Abbattista, Antonello, Martini, Jean-François, Chen, Joseph, Peltz, Gerson, Thurm, Holger, Ou, Sai-Hong Ignatius, Shaw, Alice T

Source: In The Lancet Oncology December 2018 19(12):1654-1667

A Decade of Never-smokers Among Lung Cancer Patients—Increasing Trend and Improved Survival

Authors: Toh, Chee-Keong, Ong, Whee-Sze, Lim, Wan-Teck, Tan, Daniel Shao-Weng, Ng, Quan-Sing, Kanesvaran, Ravindran, Seow, Wei-Jie, Ang, Mei-Kim, Tan, Eng-Huat

Source: In Clinical Lung Cancer September 2018 19(5):e539-e550

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

Authors: Wu, Yi-Long, Sequist, Lecia V., Tan, Eng-Huat, Geater, Sarayut L., Orlov, Sergey, Zhang, Li, Lee, Ki Hyeong, Tsai, Chun-Ming, Kato, Terufumi, Barrios, Carlos H., Schuler, Martin, Hirsh, Vera, Yamamoto, Nobuyuki, O’Byrne, Kenneth, Boyer, Michael, Mok, Tony, Peil, Barbara, Märten, Angela, Chih-Hsin Yang, James, Paz-Ares, Luis, Park, Keunchil

Source: In Clinical Lung Cancer July 2018 19(4):e465-e479

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Authors: Paz-Ares Rodriguez, Luis, Novello, Silvia, Hiret, Sandrine, Schmid, Peter, Laack, Eckart, Califano, Raffaele, Maemondo, Makoto, Kim, Sang-We, Chaft, Jamie, Vicente Baz, David, Berghmans, Thierry, Kim, Dong-Wan, Surmont, Veerle, Reck, Martin, Han, Ji-Youn, Holgado Martin, Esther, Belda Iniesta, Cristobal, Oe, Yuichiro, Chella, Antonio, Chopra, Akhil, Robinet, Gilles, Soto Parra, Hector, Thomas, Michael, Cheema, Parneet, Katakami, Nobuyuki, Su, Wu-Chou, Kim, Young-Chul, Wolf, Juergen, Lee, Jong-Seok, Saka, Hideo, Milella, Michele, Ramos Garcia, Inmaculada, Sibille, Anne, Yokoi, Takashi, Kang, Eun Joo, Atagi, Shinji, Spaeth-Schwalbe, Ernst, Nishio, Makoto, Imamura, Fumio, Gabrail, Nashat, Veillon, Remi, Derijcke, Sofie, Maeda, Tadashi, Zylla, Dylan, Kubiak, Kendra, Santoro, Armando, Uy, Ma. Noemi, Lucien Geater, Sarayut, Italiano, Antoine, Kowalski, Dariusz, Barlesi, Fabrice, Chen, Yuh-Min, Spigel, David, Chewaskulyong, Busyamas, Garcia Gomez, Ramon, Alvarez Alvarez, Rosa, Yang, Chih-Hsin, Hsia, Te-Chun, Denis, Fabrice, Sakai, Hiroshi, Vincent, Mark, Goto, Koichi, Bosch-Barrera, Joaquim, Weiss, Glen, Canon, Jean-Luc, Scholz, Christian, Aglietta, Massimo, Kemmotsu, Hirotsugu, Azuma, Koichi, Bradbury, Penelope, Feld, Ronald, Chachoua, Abraham, Jassem, Jacek, Juergens, Rosalyn, Palmero Sanchez, Ramon, Malcolm, Albert, Vrindavanam, Nandagopal, Kubota, Kaoru, Waller, Cornelius, Waterhouse, David, Coudert, Bruno, Mark, Zsuzsanna, Satouchi, Miyako, Chang, Gee-Chen, Herzmann, Christian, Chaudhry, Arvind, Giridharan, Selvaraj, Hesketh, Paul, Ikeda, Norihiko, Boccia, Ralph, Iannotti, Nichola, Haigentz, Missak, Reynolds, John, Querol, John, Nakagawa, Kazuhiko, Sugawara, Shunichi, Tan, Eng Huat, Hirashima, Tomonori, Gettinger, Scott, Kato, Terufumi, Takeda, Koji, Juan Vidal, Oscar, Mohn-Staudner, Andrea, Panwalkar, Amit, Daniel, Davey, Kobayashi, Kunihiko, Ladrera, Guia Elena Imelda, Schulte, Clemens, Sebastian, Martin, Cernovska, Marketa, Coupkova, Helena, Havel, Libor, Pauk, Norbert, Singh, Joginder, Murakami, Shuji, Csoszi, Tibor, Losonczy, Gyorgy, Price, Allan, Anderson, Ian, Iqbal, Mussawar, Torri, Vamsee, Juhasz, Erzsebet, Khanani, Saleem, Koubkova, Leona, Levy, Benjamin, Page, Ray, Bocskei, Csaba, Crinò, Lucio, Einspahr, David, Hagenstad, Christopher, Juat, Necy, Overton, Lindsay, Garrison, Mitchell, Szalai, Zsuzsanna, Garassino, Marina Chiara, Cho, Byoung-Chul, Kim, Joo-Hang, Mazières, Julien, Vansteenkiste, Johan, Lena, Hervé, Corral Jaime, Jesus, Gray, Jhanelle E, Powderly, John, Chouaid, Christos, Bidoli, Paolo, Wheatley-Price, Paul, Park, Keunchil, Soo, Ross A, Huang, Yifan, Wadsworth, Catherine, Dennis, Phillip A, Rizvi, Naiyer A

Source: In The Lancet Oncology April 2018 19(4):521-536

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

Authors: Schuler, Martin, Tan, Eng-Huat, O'Byrne, Kenneth, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Wan, Arvis, Catherine Dubos, Kölbeck, Karl, Massey, Dan, Märten, Angela, Paz-Ares, Luis, Park, Keunchil

Source: Journal of cancer research and clinical oncology. 145(6):1569-1579

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100118335201.0x000001&indx=1&recIds=ETOCvdc_100118335201.0x000001

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

Authors: Park, Keunchil, Bennouna, Jaafar, Boyer, Michael, Hida, Toyoaki, Hirsh, Vera, Kato, Terufumi, Lu, Shun, Mok, Tony, Nakagawa, Kazuhiko, O'Byrne, Kenneth, Paz-Ares, Luis, Schuler, Martin, Sibilot, Denis Moro, Tan, Eng-Huat, Tanaka, Hiroshi, Wu, Yi-Long, Yang, James C.-H., Zhang, Li, Zhou, Caicun, Märten, Angela, Tang, Wenbo, Yamamoto, Nobuyuki

Source: Lung cancer. 132:126-131

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100081856818.0x000001&indx=1&recIds=ETOCvdc_100081856818.0x000001

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients

Authors: Sutiman, Natalia, Tan, Shao Weng, Tan, Eng Huat, Lim, Wan Teck, Kanesvaran, Ravindran, Ng, Quan Sing, Jain, Amit, Ang, Mei Kim, Tan, Wan Ling, Toh, Chee Keong, Chowbay, Balram

Source: In Journal of Thoracic Oncology March 2017 12(3):529-538

Metronomic chemotherapy: A relook at its basis and rationale

Authors: Rajasekaran, Tanujaa, Ng, Quan-Sing, Tan, Daniel Shao-Weng, Lim, Wan-Teck, Ang, Mei-Kim, Toh, Chee-Keong, Chowbay, Balram, Kanesvaran, Ravindran, Tan, Eng-Huat

Source: In Cancer Letters 1 March 2017 388:328-333

Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency

Authors: Simoni, Yannick, Fehlings, Michael, Kløverpris, Henrik N., McGovern, Naomi, Koo, Si-Lin, Loh, Chiew Yee, Lim, Shawn, Kurioka, Ayako, Fergusson, Joannah R., Tang, Choong-Leong, Kam, Ming Hian, Dennis, Koh, Lim, Tony Kiat Hon, Fui, Alexander Chung Yaw, Hoong, Chan Weng, Chan, Jerry Kok Yen, Curotto de Lafaille, Maria, Narayanan, Sriram, Baig, Sonia, Shabeer, Muhammad, Toh, Sue-Anne Ee Shiow, Tan, Henry Kun Kiaang, Anicete, Rosslyn, Tan, Eng-Huat, Takano, Angela, Klenerman, Paul, Leslie, Alasdair, Tan, Daniel S.W., Tan, Iain Beehuat, Ginhoux, Florent, Newell, Evan W.

Source: In Immunity 17 January 2017 46(1):148-161

Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma—Exploration for Achieving Optimal 10-Year Therapeutic Ratio

Authors: Ng, Wai-Tong, Tung, Stewart Y., Lee, Victor, Ngan, Roger K.C., Choi, Horace C.W., Chan, Lucy L.K., Leung, To-Wai, Siu, Lillian L., Lu, Tai-Xiang, Tan, Terence, Tan, Eng-Huat, Sze, Henry C.K., Ng, Alice W.Y., Yiu, Harry H.Y., O'Sullivan, Brian, Chappell, Rick, Lee, Anne W.M.

Source: International journal of radiation oncology, biology, physics. 101(5):1078-1086

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100065430067.0x000001&indx=1&recIds=ETOCvdc_100065430067.0x000001

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing

Authors: Nahar, Rahul, Zhai, Weiwei, Zhang, Tong, Takano, Angela, Khng, Alexis, Lee, Yin, Liu, Xingliang, Lim, Chong, Koh, Tina, Aung, Zaw, Lim, Tony, Veeravalli, Lavanya, Yuan, Ju, Teo, Audrey, Chan, Cheryl, Poh, Huay, Chua, Ivan, Liew, Audrey, Lau, Dawn, Kwang, Xue, Toh, Chee, Lim, Wan-Teck, Lim, Bing, Tam, Wai, Tan, Eng-Huat, Hillmer, Axel, Tan, Daniel

Source: Nature communications. 9(1):1-11

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100103859520.0x000001&indx=1&recIds=ETOCvdc_100103859520.0x000001